Article
Potential Clinical Significance of a Plasma-Based <i>KRAS</i> Mutation Analysis in Patients with Advanced Non–Small Cell Lung Cancer
10 Feb 2010
Abstract excerpt
PURPOSE: Non-small cell lung cancer (NSCLC) with KRAS mutation may be resistant to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). This study aims to evaluate a plasma-based KRAS mutation analysis and the clinical significance of plasma KRAS mutation as a predictive marker for tumor resistance to EGFR-TKIs in patients with NSCLC. EXPERIMENTAL DESIGN: DNA extracted from plasma and matched...